search
Back to results

A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter

Primary Purpose

Coronary Artery Disease Obliterative, Chronic Total Occlusion (CTO)

Status
Completed
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Microcatheter
Sponsored by
Insight Lifetech Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coronary Artery Disease Obliterative focused on measuring microcatheter, CTO, coronary artery disease, PCI

Eligibility Criteria

26 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: i. Subjects who are >25 years of age. ii. Subjects who are able/willing to provide a written informed consent prior to participating in the clinical investigation. iii. The subject is male or, if female, is either not of childbearing potential or must use effective contraception during participation in this Clinical Investigation. iv. Subject suffering from coronary artery disease requiring percutaneous coronary angiography and/or intervention. v. Lesions classified as CTOs, meaning, TIMI 0 flow within the occluded segment and angiographic or clinical evidence or high likelihood of an occlusion duration > 3 months vi. Reference vessel diameter ≥2 mm. Exclusion Criteria: i. Coronary angiography and/or intervention contraindications. ii. Subjects with severe arrhythmia. iii. Subjects with severe systemic infection. iv. Subjects with severe coagulation disorder. v. Subjects with severe heart failure, unstable decompensated heart failure, congestive heart failure, or dyspnea who are unable to lie supine on the examination table for angiography. vi. Subjects with prior coronary artery spams or prior heart valve replacement. vii. Currently participating in an investigational drug or another device clinical investigation that has not completed the primary endpoint or that clinically interferes with the current clinical investigation endpoints.

Sites / Locations

  • Israeli-Georgian Medical Research Clinic Ltd - Healthycore Clinic
  • Tbilisi Heart and Vascular Clinic
  • Tbilisi Institute of Medicine
  • Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
  • Onassis Heart Surgery Centre
  • Red Cross General Hospital
  • National Heart Centre Singapore

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

TrueCross microcatheter

Arm Description

The TrueCross Single-use Microcatheter will be used in percutaneous coronary intervention(PCI) of the enrolled subjects.

Outcomes

Primary Outcome Measures

Clinical Performance-technical success
Angiographic confirmation of the TrueCross Single-use Microcatheter's ability to support the guidewire in crossing the CTO in the target vessel true lumen.

Secondary Outcome Measures

Safety-observation of AE
Occurrence of any device related adverse event during use of the microcatheter throughout the procedure. Occurrence of any non-device/procedure related events from screening start to the end of the procedure. This will include any events related or cause by other devices used independently from the TrueCross Single-use Microcatheter during the same PCI procedure.
Clinical Performance/Effectiveness
Angiographic confirmation of successful placement and successful injection of contrast medium into the vessel lumen, Ability of exchange of the guidewire, Safe withdrawal of the TrueCross Single-use Microcatheter. Procedural efficiency measures (procedure time and injected contrast volume).

Full Information

First Posted
September 1, 2023
Last Updated
September 1, 2023
Sponsor
Insight Lifetech Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT06030271
Brief Title
A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter
Official Title
A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
October 13, 2022 (Actual)
Primary Completion Date
March 30, 2023 (Actual)
Study Completion Date
March 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Insight Lifetech Co., Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The trial is a pivotal clinical investigation, which is a prospective, non-randomized pivotal clinical investigation to demonstrate the safety and performance of the TrueCross Single-use Microcatheter.
Detailed Description
The objective of this clinical investigation is to evaluate the performance and safety of the TrueCross Single-use Microcatheter in patients requiring a PCI procedure as well as the related clinical benefits. The study will include 59 subjects suffering from coronary artery disease requiring a percutaneous coronary intervention. Enrollment duration will be 4 months or so without follow-up. It is a single-arm trial.In the uneventual case of a potential dropout (serious protocol deviation or procedure interruption unrelated to the catheter), subjects will be replaced to reach 59 evaluable subjects for the Per Protocol population.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coronary Artery Disease Obliterative, Chronic Total Occlusion (CTO)
Keywords
microcatheter, CTO, coronary artery disease, PCI

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
TrueCross microcatheter
Arm Type
Experimental
Arm Description
The TrueCross Single-use Microcatheter will be used in percutaneous coronary intervention(PCI) of the enrolled subjects.
Intervention Type
Device
Intervention Name(s)
Microcatheter
Other Intervention Name(s)
TrueCross
Intervention Description
Support and facilitate the placement of the guidewire in the coronary artery with a CTO.
Primary Outcome Measure Information:
Title
Clinical Performance-technical success
Description
Angiographic confirmation of the TrueCross Single-use Microcatheter's ability to support the guidewire in crossing the CTO in the target vessel true lumen.
Time Frame
during the procedure
Secondary Outcome Measure Information:
Title
Safety-observation of AE
Description
Occurrence of any device related adverse event during use of the microcatheter throughout the procedure. Occurrence of any non-device/procedure related events from screening start to the end of the procedure. This will include any events related or cause by other devices used independently from the TrueCross Single-use Microcatheter during the same PCI procedure.
Time Frame
ADE: during the procedure; non-device/procedure related AE: from screening start to the end of the procedure
Title
Clinical Performance/Effectiveness
Description
Angiographic confirmation of successful placement and successful injection of contrast medium into the vessel lumen, Ability of exchange of the guidewire, Safe withdrawal of the TrueCross Single-use Microcatheter. Procedural efficiency measures (procedure time and injected contrast volume).
Time Frame
during the procedure

10. Eligibility

Sex
All
Minimum Age & Unit of Time
26 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: i. Subjects who are >25 years of age. ii. Subjects who are able/willing to provide a written informed consent prior to participating in the clinical investigation. iii. The subject is male or, if female, is either not of childbearing potential or must use effective contraception during participation in this Clinical Investigation. iv. Subject suffering from coronary artery disease requiring percutaneous coronary angiography and/or intervention. v. Lesions classified as CTOs, meaning, TIMI 0 flow within the occluded segment and angiographic or clinical evidence or high likelihood of an occlusion duration > 3 months vi. Reference vessel diameter ≥2 mm. Exclusion Criteria: i. Coronary angiography and/or intervention contraindications. ii. Subjects with severe arrhythmia. iii. Subjects with severe systemic infection. iv. Subjects with severe coagulation disorder. v. Subjects with severe heart failure, unstable decompensated heart failure, congestive heart failure, or dyspnea who are unable to lie supine on the examination table for angiography. vi. Subjects with prior coronary artery spams or prior heart valve replacement. vii. Currently participating in an investigational drug or another device clinical investigation that has not completed the primary endpoint or that clinically interferes with the current clinical investigation endpoints.
Facility Information:
Facility Name
Israeli-Georgian Medical Research Clinic Ltd - Healthycore Clinic
City
Tbilisi
Country
Georgia
Facility Name
Tbilisi Heart and Vascular Clinic
City
Tbilisi
Country
Georgia
Facility Name
Tbilisi Institute of Medicine
City
Tbilisi
Country
Georgia
Facility Name
Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic
City
Tbilisi
Country
Georgia
Facility Name
Onassis Heart Surgery Centre
City
Athens
Country
Greece
Facility Name
Red Cross General Hospital
City
Athens
Country
Greece
Facility Name
National Heart Centre Singapore
City
Singapore
Country
Singapore

12. IPD Sharing Statement

Learn more about this trial

A Prospective, Non-Randomized Pivotal Clinical Investigation to Demonstrate the Safety and Performance of the TrueCross Single-Use Microcatheter

We'll reach out to this number within 24 hrs